Pieter Droppert will be attending the Association for Research in Vision & Ophthalmology (ARVO) annual meeting that starts in Fort Lauderdale this weekend.
This meeting offers insight into future ophthalmology new products & emerging vision research. What’s interesting about the ophthalmology market is it presents opportunities not only for innovative new drugs, but also medical devices.
Pieter on Biotech Strategy Blog has written a preview of what he expects to be hot at ARVO 2011 this year.
Eagerly awaited is Sunday’s special session on the National Eye Institute Comparison of Treatments Trials (CATT). Data will be presented comparing FDA approved ranibizumab (Lucentis®) to off-label bevacizumab (Avastin®) for the treatment of neovascular age-related macular degeneration (AMD).
The results, rumoured to show comparable efficacy, have tremendous commercial implications not only for Genentech, but other companies looking to enter the AMD market such as Regeneron/Bayer with aflibercept (VEGF-Trap).
An injection using bevacizumab off-label costs around $50, compared to $1950 for FDA approved ranibizumab.
You can read further news from ARVO on Biotech Strategy Blog.